Sana Biotechnology Files 8-K for Material Agreement
Ticker: SANA · Form: 8-K · Filed: 2025-08-07T00:00:00.000Z
Sentiment: neutral
Topics: material-agreement, filing, biotech
Related Tickers: SANA
TL;DR
Sana Bio (SANA) filed an 8-K for a material agreement - big news incoming.
AI Summary
On August 6, 2025, Sana Biotechnology, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financial statements/exhibits. The company is incorporated in Delaware and headquartered in Seattle, Washington.
Why It Matters
This filing indicates a significant new agreement for Sana Biotechnology, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood by the market.
Key Numbers
- 001-39941 — Commission File Number (Identifier for SEC filings)
- 83-1381173 — IRS Employer Identification Number (Tax identification for the company)
Key Players & Entities
- Sana Biotechnology, Inc. (company) — Registrant
- August 6, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Seattle, Washington (location) — Address of principal executive offices
FAQ
What is the nature of the material definitive agreement filed by Sana Biotechnology?
The 8-K filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on August 6, 2025.
Where is Sana Biotechnology, Inc. headquartered?
Sana Biotechnology, Inc. is headquartered at 188 East Blaine Street, Suite 400, Seattle, Washington 98102.
What is Sana Biotechnology's SIC code?
Sana Biotechnology's Standard Industrial Classification (SIC) code is 2836, for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
What is the filing date of this 8-K report?
The 8-K report was filed on August 7, 2025.
Filing Stats: 1,595 words · 6 min read · ~5 pages · Grade level 12.7 · Accepted 2025-08-07 17:11:01
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share SANA The Nasdaq
- $3.35 — per share, at a price to the public of $3.35 per share (the "Underwritten Shares"),
- $3.3499 — ommon stock at a price to the public of $3.3499 per underlying share. Under the terms o
- $3.149 — n Shares from the Company at a price of $3.149 per share and the Pre-Funded Warrants a
- $3.1489 — d the Pre-Funded Warrants at a price of $3.1489 per underlying share. In addition, the
- $70.0 m — fering are expected to be approximately $70.0 million, after deducting underwriting dis
Filing Documents
- d83666d8k.htm (8-K) — 37KB
- d83666dex11.htm (EX-1.1) — 191KB
- d83666dex41.htm (EX-4.1) — 74KB
- d83666dex51.htm (EX-5.1) — 11KB
- d83666dex991.htm (EX-99.1) — 7KB
- g83666g0807233831994.jpg (GRAPHIC) — 6KB
- g83666g0808003155483.jpg (GRAPHIC) — 1KB
- g83666g0808003155723.jpg (GRAPHIC) — 3KB
- 0001193125-25-175571.txt ( ) — 534KB
- sana-20250806.xsd (EX-101.SCH) — 3KB
- sana-20250806_lab.xml (EX-101.LAB) — 18KB
- sana-20250806_pre.xml (EX-101.PRE) — 11KB
- d83666d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits See the Exhibit Index below, which is incorporated by reference herein. EXHIBIT INDEX Exhibit No. Description 1.1 Underwriting Agreement, dated as of August 6, 2025, by and among Sana Biotechnology, Inc. and the Representatives. 4.1 Form of Pre-Funded Warrant. 5.1 Opinion of Wilson Sonsini Goodrich & Rosati, P.C. 23.1 Consent of Wilson Sonsini Goodrich & Rosati, P.C. (included in Exhibit 5.1). 99.1 Press Release dated August 6, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sana Biotechnology, Inc. Date: August 7, 2025 By: /s/ Bernard J. Cassidy Bernard J. Cassidy Executive Vice President and General Counsel